IS7488A - Dreyfasamsetning í föstu formi - Google Patents

Dreyfasamsetning í föstu formi

Info

Publication number
IS7488A
IS7488A IS7488A IS7488A IS7488A IS 7488 A IS7488 A IS 7488A IS 7488 A IS7488 A IS 7488A IS 7488 A IS7488 A IS 7488A IS 7488 A IS7488 A IS 7488A
Authority
IS
Iceland
Prior art keywords
solid formulation
formulation
solid
Prior art date
Application number
IS7488A
Other languages
English (en)
Inventor
Takano Niichiro
Kawashima Hiroyuki
Shinoda Yasuo
Inagi Toshio
Original Assignee
Kowa Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co., Ltd. filed Critical Kowa Co., Ltd.
Publication of IS7488A publication Critical patent/IS7488A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
IS7488A 2002-04-16 2004-10-04 Dreyfasamsetning í föstu formi IS7488A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37241602P 2002-04-16 2002-04-16
PCT/JP2003/004762 WO2003086405A1 (fr) 2002-04-16 2003-04-15 Composition de dispersion solide

Publications (1)

Publication Number Publication Date
IS7488A true IS7488A (is) 2004-10-04

Family

ID=29250849

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7488A IS7488A (is) 2002-04-16 2004-10-04 Dreyfasamsetning í föstu formi

Country Status (22)

Country Link
US (1) US6753330B2 (is)
EP (1) EP1495759A4 (is)
JP (1) JP4295629B2 (is)
KR (1) KR20040101437A (is)
CN (1) CN1291719C (is)
AU (1) AU2003235156B2 (is)
BR (1) BR0309212A (is)
CA (1) CA2481595A1 (is)
EA (1) EA007153B1 (is)
HK (1) HK1082669A1 (is)
HR (1) HRP20040959A2 (is)
IL (2) IL164206A0 (is)
IS (1) IS7488A (is)
MX (1) MXPA04010174A (is)
MY (1) MY128945A (is)
NO (1) NO20044337L (is)
NZ (1) NZ535541A (is)
PL (1) PL372980A1 (is)
TW (1) TWI319772B (is)
UA (1) UA79610C2 (is)
WO (1) WO2003086405A1 (is)
ZA (1) ZA200407657B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096281A1 (ja) * 2003-04-29 2004-11-11 Kowa Co., Ltd. 溶出性に優れた超難水溶性薬物含有組成物及びその製造法
US20070021418A1 (en) * 2003-07-30 2007-01-25 Kowa Co., Ltd. Method of inhibiting production of osteopontin
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition
JP2006001859A (ja) * 2004-06-16 2006-01-05 Shiseido Co Ltd 絆創膏組成物
US20090005384A1 (en) * 2005-01-25 2009-01-01 Kowa Co., Ltd Method for Producing Adsorptive Porous Body
CN101242831A (zh) * 2005-08-31 2008-08-13 兴和株式会社 类风湿性关节炎的预防和/或治疗方法
WO2008064259A2 (en) * 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
JP2009155282A (ja) * 2007-12-27 2009-07-16 Kowa Co 固体分散体含有医薬組成物
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2019241077A1 (en) * 2018-06-11 2019-12-19 Abon Pharmaceuticals Llc. Oral eliglustat transmucosal delivery system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019239A1 (fr) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Composition solide a solubilite et absorbabilite ameliorees
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
JP3335132B2 (ja) * 1997-11-19 2002-10-15 興和株式会社 新規ピリダジン誘導体及びこれを有効成分とする医薬
EP2017266A1 (en) * 1997-11-19 2009-01-21 Kowa Co., Ltd. Pyridazine derivatives and medicines containing the same as effective ingredients
BR0014469A (pt) * 1999-10-04 2002-06-11 Asahi Chemical Ind Processo para melhorar a solubilidade de um derivado de amino álcool tricìclico, composição farmacêutica, processo para preparar a mesma, e, derivado de amino álcool tricìclico
JP2004131393A (ja) * 2002-10-08 2004-04-30 Kowa Co 易溶出性製剤

Also Published As

Publication number Publication date
HK1082669A1 (en) 2006-06-16
IL164206A0 (en) 2005-12-18
NO20044337L (no) 2004-10-12
TW200408671A (en) 2004-06-01
MXPA04010174A (es) 2005-02-03
MY128945A (en) 2007-03-30
EA200401377A1 (ru) 2005-06-30
CN1646128A (zh) 2005-07-27
HRP20040959A2 (en) 2004-12-31
UA79610C2 (en) 2007-07-10
AU2003235156B2 (en) 2007-07-05
WO2003086405A1 (fr) 2003-10-23
JPWO2003086405A1 (ja) 2005-08-18
AU2003235156B9 (en) 2003-10-27
IL164206A (en) 2008-04-13
PL372980A1 (en) 2005-08-08
BR0309212A (pt) 2005-02-09
NZ535541A (en) 2006-09-29
JP4295629B2 (ja) 2009-07-15
TWI319772B (en) 2010-01-21
AU2003235156A1 (en) 2003-10-27
KR20040101437A (ko) 2004-12-02
EP1495759A1 (en) 2005-01-12
EP1495759A4 (en) 2010-12-29
US20040019122A1 (en) 2004-01-29
CN1291719C (zh) 2006-12-27
CA2481595A1 (en) 2003-10-23
ZA200407657B (en) 2006-07-26
EA007153B1 (ru) 2006-08-25
US6753330B2 (en) 2004-06-22

Similar Documents

Publication Publication Date Title
DK3536344T3 (da) Superfin formoterolformulering
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DK1551802T3 (da) Indol-3-svovlderivater
ATE467631T1 (de) Chinuclidinamidderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
ATE438644T1 (de) Chinazolinderivate
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
ATE368042T1 (de) Cephemverbindungen
DE10393374D2 (de) Zusammensetzung
SE0500163L (sv) Sammansättning
IS7381A (is) Efnasambönd
IS7414A (is) Oxó-azabísýklísk efnasambönd
DK1561472T3 (da) Faststofsammensætning
DE60320902D1 (de) Zusammensetzungen mit ausgelöster Freisetzung
DE60327447D1 (de) Pflaster
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
NO20045659L (no) Forbindelser
DK1492934T3 (da) Dørenhed
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
IS7488A (is) Dreyfasamsetning í föstu formi
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
DE60328488D1 (de) Ng
DE60321745D1 (de) Multipolarer Magnetogenerator